Table 2 Molecular, treatment with imatinib and cytogenetic assessment of clinical samples of CML patients studied
| Â | No. of Patients | Group A (n57) | Group B (n30) | Group C (n4) |
|---|---|---|---|---|
Variations in BCR-ABL/BCR % | Â | Â | Â | Â |
0.5-< 1 | 19 | 0 | 19 | 0 |
1-10 | 13 | 0 | 11 | 2 |
> 10 | 2 | 0 | 0 | 2 |
Imatinib dose during follw up until achievement of CCyR | Â | Â | Â | Â |
No change | 68 | 45 | 21 | 2 |
Dose escalation | 18 | 9 | 7 | 2 |
Dose reduction | 5 | 3 | 2 | 0 |
Loss of CCyR | 2 | 0 | 0 | 2 |
Alteration in Ph negative cells | 5 | 4 | 1 | 0 |
Achievement of CMR | 39 | 29 | 10 | 0 |